Tidutamab

Cat. No.:	HY-P99562
CAS No.:	2148354-90-7
Target:	CD3
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC)[1].
In Vitro	Tidutamab (XmAb-18087; 0-100.000 ng/mL) binds to human SSTR2+ CHO cells with an ED_{50} value of 2.2 μg/mL and mediates T cell killing of SSTR2+ target cells[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Tidutamab (XmAb-18087; 3 mg/kg; i.p.; single dose) stimulates human T cell killing of SSTR2+ A549 lung carcinoma tumors in NSG mice[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NSG mice[1]
Dosage:	3 mg/kg
Administration:	Intraperitoneal injection; single dose
Result:	Induced anti-tumor activity in human PBMC-engrafted NSG mice.

REFERENCES

[1]. Hyung LS, et, al. Anti-SSTR2 × anti-CD3 bispecific antibody induces potent killing of human tumor cells in vitro and in mice, and stimulates target-dependent T cell activation in monkeys: A potential immunotherapy for neuroendocrine tumors. Cancer Res (2017) 77 (13_Supplement): 3633.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA